JW Asset Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-388,392
Closed -$12.2M – 30
2026
Q2
$12.2M Hold
388,392
– – 3.82% 4
2026
Q1
$9.6M Hold
388,392
– – 3.95% 3
2025
Q4
$9.07M Hold
388,392
– – 2.95% 4
2025
Q3
$7.65M Hold
388,392
– – 3.67% 6
2025
Q2
$8.43M Sell
388,392
-25,000
-6% -$590K 4.15% 5
2025
Q1
$10M Hold
413,392
– – 5.68% 2
2024
Q4
$8.63M Hold
413,392
– – 4.1% 5
2024
Q3
$8.22M Hold
413,392
– – 3.71% 5
2024
Q2
$6.4M Hold
413,392
– – 2.64% 8
2024
Q1
$6.59M Hold
413,392
– – 2.41% 9
2023
Q4
$6.95M Sell
413,392
-150,000
-27% -$2.05M 3.97% 7
2023
Q3
$6.59M Hold
563,392
– – 2.85% 6
2023
Q2
$7.57M Hold
563,392
– – 2.76% 5
2023
Q1
$9.34M Hold
563,392
– – 3.58% 3
2022
Q4
$10.5M Buy
+563,392
New +$8.67M 4.31% 2

Other funds holding CPRX

JW Asset Management's CPRX Position: Q3 2026 in Review

JW Asset Management sold out of Catalyst Pharmaceutical (CPRX) in Q3 2026, closing a stake of 388,392 shares — an estimated $12.2M sold.

JW Asset Management first reported a position in CPRX in Q4 2022 and held it in 15 quarters. The position peaked at $12.2M in Q2 2026. 3 funds tracked by Wall St. Rank hold CPRX as of Q3 2026.

  • JW Asset Management reported no remaining Catalyst Pharmaceutical position as of Q3 2026 after selling out during the quarter.
  • JW Asset Management sold 388,392 Catalyst Pharmaceutical shares in Q3 2026, an estimated $12.2M.
  • JW Asset Management first reported a position in Catalyst Pharmaceutical in Q4 2022 and held it in 15 quarters.
  • JW Asset Management's Catalyst Pharmaceutical position peaked at $12.2M in Q2 2026.
  • 3 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2026.

Based on JW Asset Management's 13F filing for Q3 2026, filed 6 Nov 2026.